Targeting methionine cycle as a potential therapeutic strategy for immune disorders
文献类型：期刊论文
| 作者 | Li, Heng1,2; Lu, Huimin1,2; Tang, Wei1,2 ; Zuo, Jianping1,2
|
| 刊名 | EXPERT OPINION ON THERAPEUTIC TARGETS
 |
| 出版日期 | 2017 |
| 卷号 | 21期号:9页码:861-877 |
| 关键词 | Methionine cycle S-adenosylhomocysteine hydrolase inhibitors rheumatoid arthritis systemic lupus erythematosus immunosuppression epigenetic regulation plasma homocysteine |
| ISSN号 | 1472-8222 |
| DOI | 10.1080/14728222.2017.1370454 |
| 文献子类 | Review |
| 英文摘要 | Introduction: Methionine cycle plays an essential role in regulating many cellular events, especially transmethylation reactions, incorporating the methyl donor S-adenosylmethionine (SAM). The transmethylations and substances involved in the cycle have shown complicated effects and mechanisms on immunocytes developments and activations, and exert crucial impacts on the pathological processes in immune disorders. Areas covered: Methionine cycle has been considered as an effective means of drug developments. This review discussed the role of methionine cycle in immune responses and summarized the potential therapeutic strategies based on the cycle, including SAM analogs, methyltransferase inhibitors, S-adenosylhomocysteine hydrolase (SAHH) inhibitors, adenosine receptors specific agonists or antagonists and homocysteine (Hcy)-lowering reagents, in treating human immunodeficiency virus (HIV) infections, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), systemic sclerosis (SSc) and other immune disorders. Expert opinion: New targets and biomarkers grown out of methionine cycle have developed rapidly in the past decades. However, impacts of epigenetic regulations on immune disorders are unclear and whether the substances in methionine cycle can be clarified as biomarkers remains controversial. Therefore, further elucidation on the role of epigenetic regulations and substances in methionine cycle may contribute to exploring the cycle-derived biomarkers and drugs in immune disorders. |
| WOS关键词 | ADENOSYL-L-HOMOCYSTEINE ; SYSTEMIC-LUPUS-ERYTHEMATOSUS ; INFLAMMATORY-BOWEL-DISEASE ; T-CELL-ACTIVATION ; S-ADENOSYLHOMOCYSTEINE HYDROLASE ; ARTHRITIS SYNOVIAL FIBROBLASTS ; AUTOIMMUNE RHEUMATIC-DISEASES ; INTESTINAL EPITHELIAL-CELLS ; NF-KAPPA-B ; DNA METHYLATION |
| 资助项目 | Chinese Academy of Sciences[XDA12020215] ; National Key Basic Research Programme[2014CB541906] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000408352000004 |
| 出版者 | TAYLOR & FRANCIS LTD |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/275701]  |
| 专题 | 药理学第一研究室 中科院受体结构与功能重点实验室 新药研究国家重点实验室 |
| 通讯作者 | Tang, Wei; Zuo, Jianping |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Lab Immunopharmacol, State Key Lab Drug Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China; 2.Univ Chinese Acad Sci, Coll Pharm, Beijing, Peoples R China |
| 推荐引用方式 GB/T 7714 | Li, Heng,Lu, Huimin,Tang, Wei,et al. Targeting methionine cycle as a potential therapeutic strategy for immune disorders[J]. EXPERT OPINION ON THERAPEUTIC TARGETS,2017,21(9):861-877. |
| APA | Li, Heng,Lu, Huimin,Tang, Wei,&Zuo, Jianping.(2017).Targeting methionine cycle as a potential therapeutic strategy for immune disorders.EXPERT OPINION ON THERAPEUTIC TARGETS,21(9),861-877. |
| MLA | Li, Heng,et al."Targeting methionine cycle as a potential therapeutic strategy for immune disorders".EXPERT OPINION ON THERAPEUTIC TARGETS 21.9(2017):861-877. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。